Japan Blood Products Organization

Executive Summary

Japan Blood Products Organization (JB) is a non-profit entity dedicated to ensuring a stable supply of safe, blood-derived pharmaceuticals in Japan. Established in 2020, it specializes in plasma fractionation and biologics for hematological and rare diseases. As the sole domestic processor of blood products, JB plays a critical role in national health security, reducing reliance on imports. Its operations encompass collection, processing, and distribution, with a focus on quality and reliability. Despite being non-profit, JB's strategic importance positions it for government support and collaboration. Recent investments in modernization and capacity expansion aim to enhance efficiency and meet growing demand for plasma-derived therapies, including immunoglobulins and clotting factors.

Upcoming Catalysts (preview)

• Q3 2026Approval for new plasma fractionation facility80% success
• TBDPartnership with a global biopharma for technology transfer60% success